A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study)

• Results Overview

  People using tacrolimus or pimecrolimus creams for eczema had a slightly higher risk of developing lymphoma compared to those using corticosteroid creams, but the actual number of cases was very small, suggesting minimal risk for individual patients.

• Study Summary

  Num Participants:

  988,527

  Study Type:

  Observational

  Control Group:

  Moderate- To High-Potency Topical Corticosteroid Users And Untreated Subjects

  Efficacy End Points Treatment:

  {'Lymphoma incidence - tacrolimus children': 10.4, 'Lymphoma incidence - tacrolimus adults': 41.0, 'Lymphoma incidence - pimecrolimus children': 3.0, 'Lymphoma incidence - pimecrolimus adults': 27.0}

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected